Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
As FDA makes Lipfendra poster child of CNPV pilot, Merck charts long-term path for first PCSK9 pill
Long viewed as one of the biggest hype-to-disappointment stories in pharmaceutical history, the PCSK9 cholesterol drug class has struggled to live up to its commercial promise. Merck & Co. | The PCSK9 cholesterol drug class has long been viewed as one of the biggest hype-to-disappointment stories in pharmaceutical history. Merck aims to flip that narrative with Lipfendra, betting the first-ever oral option can finally unlock the market’s full potential with support from regulators and doctors.
TL;DRAI
Merck's Lipfendra becomes first oral PCSK9 with FDA CNPV approval, priced at $315/month—50% below injectable rivals—targeting $5B peak sales. PCSK9 class remained at 5% penetration despite clinical proof for a decade; Lipfendra's success hinges on insurance reimbursement policy and physician habit change, not drug efficacy.
913 words~4 min read
